Prof. Ido Wolf

Patients often reach out after they’ve already received a diagnosis and sometimes even after treatment has started. Gastric cancer can behave very differently depending on stage, tumor biology, and overall health.

In some cases, reviewing pathology and imaging again may open additional treatment options. Sometimes the original plan remains the right one — but it’s still important to look carefully at all available data before moving forward.

Every case is unique, and treatment decisions should always be made after a thorough evaluation.

Over the past few years, treatment for colorectal cancer has evolved significantly. Today, we often consider targeted therapies, immunotherapy, and molecular-guided treatment strategies.

Not all patients benefit from the same approach. Factors such as tumor genetics, disease stage, and previous treatments all influence decision-making.

In some cases, additional testing may help identify new treatment possibilities.

Immunotherapy can be effective for certain types of gastrointestinal cancers, including some cases of gastric cancer and colorectal cancer. However, it does not work for everyone.

We usually rely on molecular testing to understand whether immunotherapy is likely to help. This includes evaluating markers such as MSI status or other biological characteristics.

Treatment decisions are always individualized and based on multiple factors.

Liver cancer treatment has changed considerably in recent years. In addition to traditional therapies, new systemic treatments and combination approaches are now available.

In some cases, targeted therapy or immunotherapy may be considered. In others, local treatments or combined strategies may be more appropriate.

The optimal approach depends on tumor characteristics, liver function, and overall patient condition.

Advanced cancer usually refers to disease that has spread locally or to distant organs. This can sound alarming, but treatment options still exist in many situations.

Today, we often consider multiple strategies — systemic therapy, targeted treatment, immunotherapy, or clinical trials. The goal is to control disease and maintain quality of life.

Each situation is different, and treatment decisions depend on individual factors.

Metastatic cancer does not always mean that treatment options are limited. In fact, many patients today receive effective therapies even in advanced stages.

Modern oncology focuses on controlling disease, prolonging survival, and maintaining quality of life. In some cases, long-term disease control is possible.

Treatment strategies depend on tumor biology, spread pattern, and patient condition.

Molecular testing helps us better understand the biology of the tumor. This can sometimes identify targeted treatment options that would not otherwise be considered.

Testing is often recommended in advanced or metastatic cancer, particularly when standard treatment options are limited.

These decisions are made individually and based on clinical context.

Clinical trials evaluate new therapies and treatment combinations. For some patients, participation in a clinical trial may provide access to new treatments.

However, clinical trials are not suitable for everyone. Eligibility depends on medical criteria and overall condition.

Careful evaluation is always necessary before considering this option.